

ASX ANNOUNCEMENT

9 March 2021

Cann Group supplies medicinal cannabis for Australian clinical trial assessing quality of life impacts for advanced cancer patients

- **Phase I/II trial being led by Olivia Newton-John Cancer Research Institute**
 - **Efficacy outcomes to be assessed in 108 patients**
 - **Funding support from Victorian Cancer Agency/Victorian Government**
-

9 March 2021 – Cann Group Limited (ASX: CAN) and the Olivia Newton-John Cancer Research Institute (ONJCRI), as the La Trobe School of Cancer Medicine, and Austin Health, announced today that they have partnered in a clinical trial to assess medicinal cannabis for symptom management in people with advanced cancer.

The Phase I trial commenced in late September 2020 and trial outcomes are currently being reviewed, with patients having tolerated the treatment well to date. Phase I is focused on the titration and safety of administering this new formulation of medicinal cannabis in a controlled manner.

Should the Phase I study demonstrate safety and tolerability of the drug, Phase II (a double blind, randomised, placebo-controlled trial) will see the enrolment of 108 participants with advanced cancers, subject to meeting trial specific eligibility criteria. The Phase II study will evaluate the efficacy of the drug by assessing global Quality of Life in these participants, as well as other domains including pain, anorexia, nausea, anxiety and sleep. Participants can only be referred to the study by their treating physician.

Cann Group would like to recognise the tremendous advocacy of Dame Olivia Newton-John DBE, AC for this trial and gratefully acknowledge the generous support of the Victorian Cancer Agency who funded this trial, which was initiated by ONJCRI's Prof Jonathan Cebon. This project is a strong collaborative effort between ONJCRI (sponsor and manager of the trial) and Austin Health to develop the protocol; ONJCRI Coordinating Principal Investigator and Austin Health Principal Investigator Dr Aaron Wong (Palliative Care Physician) who has fostered the collaboration with other sites and university stakeholders; and Cann Group who is supplying a locally cultivated and manufactured product for the trial.

Cann Group's product is from a strain that was initially developed by Agriculture Victoria. It is a full spectrum cannabis extract that contains both cannabidiol (CBD) and tetrahydrocannabinol (THC) formulated into an oil that is taken up to three times a day.

Cann Group CEO Peter Crock said the Company is pleased to be able to contribute to the ongoing clinical evaluation of medicinal cannabis as a potential therapy for cancer patients, through supply of the trial's investigational product.

“There is a large and growing body of anecdotal evidence supporting the role of medicinal cannabis in pain control, reducing nausea and treating other side-effects and quality of life outcomes associated with cancer treatment. It is important, however, that we continue to build a solid body of evidence via rigorously controlled clinical trials such as this.”

ONJCRI’s Director Prof Matthias Ernst said: “This is a first-of-its-kind clinical trial in Victoria and one of only a few being conducted world-wide. As a team, we are incredibly excited to be leading this trial. As with all of our other research efforts, we are focussed on finding new options for people impacted by cancer.”

Full details about the trial are available at:

<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378487&isReview=true>

Authorised for release by the Board of Directors, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420

matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088

contact@canngrouponlimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088

contact@canngrouponlimited.com

Jaime Greenup
Communications and Engagement Manager
Olivia Newton-John Cancer Research Institute
+61 405 341 792

jaime.greenup@onjcri.org.au

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. The company has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation facility near Mildura, Victoria. Cann Group has executed collaboration agreements that have enabled it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products. **Learn more about Cann Group at www.canngrouponlimited.com**

About the Olivia Newton-John Cancer Research Institute

The Olivia Newton-John Cancer Research Institute, as the La Trobe University School of Cancer Medicine, is a leader in the development of experimental and breakthrough cancer treatments. We investigate and develop treatments for cancers of the breast, bowel and gastrointestinal tract, lung, skin, prostate, liver and brain. Our researchers and clinician scientists lead clinical trials, giving patients access to potential new treatments including immunotherapies and personalised medicine. We are integrated within the Olivia Newton-John Cancer Centre, with research laboratories only metres away from where patients are cared for and receive treatment. This inspires and enables the rapid translation of our scientific discovery into clinical trials of new, better, cancer treatments. **Learn more about ONJCRI at www.onjcri.org.au**